

# Table of Contents

<b>Acknowledgment</b> .....	<b>v</b>
<b>Table of Contents</b> .....	<b>xi</b>
<b>List of Figures</b> .....	<b>xvii</b>
<b>List of Tables</b> .....	<b>xxi</b>
<b>List of Abbreviations</b> .....	<b>xxii</b>
<b>List of Symbols</b> .....	<b>xxiii</b>
<b>Abstract</b> .....	<b>xxiv</b>
<b>Chapter 1: General Introduction</b> .....	<b>1</b>
<b>1.1 Introduction</b> .....	<b>2</b>
<b>1.2 Epidemiology</b> .....	<b>5</b>
1.2.1 Local prevalence .....	5
1.2.2 Worldwide prevalence .....	6
1.2.3 Survival.....	7
<b>1.3 Etiology and pathophysiology</b> .....	<b>7</b>
<b>1.4 Biological markers of depression and MI</b> .....	<b>10</b>
1.4.1 Cortisol/corticosterone.....	11
1.4.2 Serotonin.....	12
1.4.3 Brain derived neurotrophic factor (BDNF) .....	12
1.4.4 Cardiac troponin-I &T .....	15
1.4.5 Creatine kinase-MB and lactate dehydrogenase.....	16
1.4.6 Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) .....	16
1.4.7 Matrix Metalloproteinase 2 (MMP2).....	17
<b>1.5 Management approaches</b> .....	<b>17</b>
1.5.1 Selective serotonin reuptake inhibitors (SSRIs) .....	18
1.5.2 Tricyclic antidepressants (TCAs) .....	19
1.5.3 Selective norepinephrine reuptake inhibitors (SNRIs) .....	20
1.5.4 Monoamine oxidase inhibitors (MAOIs) .....	20

<b>1.6 Rosmarinic acid .....</b>	<b>22</b>
<b>1.7 Aims .....</b>	<b>23</b>
<b>1.8 Hypothesis .....</b>	<b>23</b>

**Chapter 2: Prophylactic administration of rosmarinic acid ameliorates CUS-associated cardiac abnormalities in Wistar rats .....1**

**2.1 Introduction .....27**

**2.2 Materials and methods.....29**

2.2.1 Animals..... 29

2.2.2 Drug preparation and treatment..... 29

2.2.6 Experimental design ..... 29

2.2.3 Chronic unpredictable stress exposure ..... 30

2.2.4 Body weight..... 32

2.2.5 Electrocardiography..... 32

2.2.7 Forced swim test..... 32

2.2.8 Sucrose preference test ..... 33

2.2.9 Collection of tissues and tissue homogenation..... 33

2.2.10 Estimation of plasma corticosterone level ..... 33

2.2.11 Estimation of serotonin level in prefrontal cortex ..... 34

2.2.12 Estimation of cTn-I and MMP-2 ..... 34

2.2.13 Estimation of oxidative stress in brain and heart tissues ..... 34

2.2.14 Estimation of pro-inflammatory cytokines ..... 35

2.2.15 Statistical analysis..... 35

**2.3 Results.....36**

2.3.1 Effects of rosmarinic acid on immobility period and sucrose preference..... 36

2.3.2 Effects of rosmarinic acid on body weight ..... 37

2.3.3 Effects of rosmarinic acid on brain, heart, and adrenal gland weight ..... 38

2.3.4 Effects of rosmarinic acid on corticosterone and serotonin levels ..... 39

2.3.5 Effects of rosmarinic acid on cardiac abnormalities..... 40

2.3.6 Effects of rosmarinic acid on cardiac biomarkers in serum and heart tissue ..... 43

2.3.7 Effects of rosmarinic acid on oxidative stress in brain and heart ..... 43

2.3.7.1 Effects of rosmarinic acid on lipid peroxidation ..... 43

2.3.7.2 Effects of rosmarinic acid on glutathione level..... 44

2.3.7.3 Effects of rosmarinic acid on catalase activity ..... 44

2.3.8 Effects of rosmarinic acid on pro-inflammatory cytokines .....	46
<b>2.4 Discussion .....</b>	<b>47</b>
<b>2.5 Conclusion .....</b>	<b>51</b>
<b>Chapter 3: Evaluation of rosmarinic acid against myocardial infarction in maternally separated rats .....</b>	<b>27</b>
<b>3.1 Introduction.....</b>	<b>54</b>
<b>3.2 Materials and methods .....</b>	<b>56</b>
3.2.1 Animals and Housing .....	56
3.2.2 Maternal Separations .....	57
3.2.3 Chemicals .....	57
3.2.4 Induction of experimental myocardial infarction .....	57
3.2.5 Experimental design.....	58
3.2.6 Body weight .....	59
3.2.7 Electrocardiography .....	59
3.2.8 Forced swim test .....	60
3.2.9 Sucrose preference test .....	60
3.2.10 Collection of blood, tissues, and homogenate preparation .....	61
3.2.11 Estimation of biochemical parameters .....	61
3.2.12 Estimation of level of antioxidative enzymes .....	61
3.2.13 Statistical analysis .....	62
<b>3.3 Results.....</b>	<b>63</b>
3.3.1 Effect of rosmarinic acid on behavioral test .....	63
331 1 Effect of rosmarinic acid on forced swim test and sucrose preference test	63
332 Effect of rosmarinic acid on body weight .....	64
3.3.2 Effect of rosmarinic acid on biochemical parameters.....	66
331 Effect of rosmarinic acid on plasma corticosterone .....	66
332 Effect of rosmarinic acid on BDNF and IL-10 levels .....	67
333 Effect of rosmarinic acid on plasma CKMB and LDH levels.....	68
3.3.3 Effect of rosmarinic acid on oxidative stress parameters .....	70
3.3.4 Effect of rosmarinic acid on ST-segment elevation .....	72
<b>3.4 Discussion .....</b>	<b>75</b>
<b>1.9 Conclusion .....</b>	<b>82</b>
<b>Chapter 4: Effect of rosmarinic acid against combined stress-induced cardiac</b>	

<b>abnormalities in Wistar rats validated using in-silico and experimental studies....</b>	<b>54</b>
<b>4.1 Introduction .....</b>	<b>85</b>
<b>4.2 Materials and methods.....</b>	<b>88</b>
4.2.1 <i>In silico</i> study.....	88
4.2.1.1 Network Pharmacology .....	88
4.2.1.2 Docking .....	88
4.2.2 Animals and Housing .....	89
4.2.3 Experimental design .....	89
4.2.3.1 Maternal separation and CUS exposure .....	90
4.2.3.2 Drug preparation and treatment.....	91
4.2.3.3 Forced swim test and sucrose preference test.....	91
4.2.3.4 Body weight .....	91
4.2.4 Electrocardiography.....	91
4.2.4 Determination of heart weight index .....	92
4.2.5 Biochemical Analysis .....	92
4.2.5.1 Estimation of plasma corticosterone using HPLC-UV.....	92
4.2.5.2 Enzyme linked immunosorbent assay and diagnostic kits .....	92
4.2.5.3 Estimation of imbalance in oxidative stress and antioxidative systems .....	93
4.2.5.4 Platelet and platelet rich plasma (PRP) isolation.....	93
4.2.5.5 <i>In-vitro</i> platelet aggregation .....	94
4.2.5.6 RNA isolation and gene expression .....	94
4.2.5.7 Histopathology .....	95
4.2.6 Statistical analysis.....	96
<b>4.3 Results.....</b>	<b>97</b>
4.3.1 Network Pharmacology Analysis .....	97
4.3.1.1 <i>Target prediction results</i> .....	97
4.3.1.2 Protein–protein interaction .....	98
4.3.1.3 Gene Enrichment Analysis.....	98
4.3.2 Docking .....	101
4.3.2.1 Rosmarinic acid exhibited binding affinity with MMP2, STAT3, TrkB, P2Y12, and TXA2 receptors .....	101
4.3.2.2 Interaction of rosmarinic acid and fluoxetine with receptors residues .....	102
4.3.3 Rosmarinic acid decreased immobility period and anhedonia behavior.....	107
4.3.4 Rosmarinic acid decreased CORT level and increased BDNF and 5-HT level..	110
4.3.5 <i>Rosmarinic acid increased body weight, organ weight, and heart weight index</i>	111
4.3.6 Rosmarinic acid inhibited platelet aggregation.....	113
4.3.7 Rosmarinic acid alleviated cardiac abnormalities.....	115
4.3.8 Rosmarinic acid decreased cardiac biomarkers .....	119

4.3.9 Rosmarinic acid decreased SOD activity and increased MDA and nitrite level.	121
4.3.10 Rosmarinic acid increased anti-inflammatory and decreased pro inflammatory cytokine levels .....	123
4.3.11 Histopathology.....	124
<b>4.4 Discussion .....</b>	<b>125</b>
<b>4.5 Conclusion .....</b>	<b>131</b>
<b>Chapter 5: Summary, conclusions and scope for further work.....</b>	<b>132</b>
<b>5.1 Summary and conclusions.....</b>	<b>133</b>
<b>5.2 Scope for further work .....</b>	<b>134</b>
<b>Chapter 6: References .....</b>	<b>136</b>
<b>Chapter 7: Publications.....</b>	<b>168</b>
<b>7.1 Research papers .....</b>	<b>169</b>
<b>7.2 Coauthor paper .....</b>	<b>169</b>
<b>7.3 Book Chapters.....</b>	<b>170</b>
<b>7.4 Conference abstracts .....</b>	<b>170</b>
<b>Chapter 8: Appendix .....</b>	<b>171</b>
<b>8.1 Ethical clearance certificate 1 .....</b>	<b>172</b>
<b>8.2 Ethical clearance certificate 2 .....</b>	<b>173</b>
<b>8.3 Ethical clearance certificate 3 .....</b>	<b>174</b>